[go: up one dir, main page]

GR3022065T3 - Novel antibodies and methods for their use - Google Patents

Novel antibodies and methods for their use

Info

Publication number
GR3022065T3
GR3022065T3 GR960403510T GR960403510T GR3022065T3 GR 3022065 T3 GR3022065 T3 GR 3022065T3 GR 960403510 T GR960403510 T GR 960403510T GR 960403510 T GR960403510 T GR 960403510T GR 3022065 T3 GR3022065 T3 GR 3022065T3
Authority
GR
Greece
Prior art keywords
methods
novel antibodies
antibodies
novel
Prior art date
Application number
GR960403510T
Other languages
English (en)
Inventor
Beverley Jane Randle
Original Assignee
Surface Active Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919108954A external-priority patent/GB9108954D0/en
Priority claimed from GB929207192A external-priority patent/GB9207192D0/en
Application filed by Surface Active Ltd filed Critical Surface Active Ltd
Publication of GR3022065T3 publication Critical patent/GR3022065T3/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/972—Modified antibody, e.g. hybrid, bifunctional
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/819—Multifunctional antigen or antibody

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
GR960403510T 1991-04-26 1996-12-17 Novel antibodies and methods for their use GR3022065T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919108954A GB9108954D0 (en) 1991-04-26 1991-04-26 Immunoassay method and antibodies for use in such methods
GB929207192A GB9207192D0 (en) 1992-04-01 1992-04-01 Antibodies

Publications (1)

Publication Number Publication Date
GR3022065T3 true GR3022065T3 (en) 1997-03-31

Family

ID=26298788

Family Applications (1)

Application Number Title Priority Date Filing Date
GR960403510T GR3022065T3 (en) 1991-04-26 1996-12-17 Novel antibodies and methods for their use

Country Status (17)

Country Link
US (2) US5573920A (el)
EP (2) EP0511011B1 (el)
JP (1) JP3431140B2 (el)
CN (1) CN1047666C (el)
AP (1) AP257A (el)
AT (1) ATE144624T1 (el)
AU (1) AU665758B2 (el)
CA (1) CA2108451A1 (el)
DE (1) DE69214709T2 (el)
DK (1) DK0511011T3 (el)
ES (1) ES2093778T3 (el)
GR (1) GR3022065T3 (el)
HU (1) HUT66753A (el)
IE (1) IE921342A1 (el)
IL (1) IL101690A (el)
NZ (1) NZ242510A (el)
WO (1) WO1992019973A1 (el)

Families Citing this family (299)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316369D0 (en) * 1993-08-06 1993-09-22 Surface Active Ltd Diagnostic method
GB9421468D0 (en) * 1994-10-18 1994-12-07 Surface Active Ltd Biosensor
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
FR2736642B1 (fr) * 1995-07-10 1997-09-12 Pasteur Institut Immunovecteurs, notamment anticorps et fragments d'anticorps utilisables pour le transport intracellulaire et intranucleaire de principes biologiquement actifs notamment d'haptenes, de proteines et d'acides nucleiques
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
FI100276B (fi) * 1996-02-06 1997-10-31 Orion Yhtymae Oy Menetelmä analyyttien ei-kilpailevaa määritystä varten
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) * 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
AU757694B2 (en) * 1997-09-05 2003-03-06 Southern Medical Diagnostics Pty Ltd A method of diagnosis
ATE476662T1 (de) 1997-09-05 2010-08-15 Southern Medical Diagnostics P Diagnoseverfahren
US20060166276A1 (en) * 1997-09-05 2006-07-27 Lung Health Diagnostics Pty Ltd Method of diagnosis and agents useful for same
CN1316910A (zh) * 1998-02-19 2001-10-10 埃克斯西特治疗公司 用于调节淋巴细胞活化的组合物及方法
EP1982990A1 (en) 1998-03-19 2008-10-22 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6171802B1 (en) * 1998-06-10 2001-01-09 Kent State University Detection and amplification of ligands
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US7833528B2 (en) 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
WO1999066951A2 (en) * 1998-06-22 1999-12-29 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7138103B2 (en) 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7052872B1 (en) 1999-06-22 2006-05-30 Immunomedics, Inc. Bi-specific antibodies for pre-targeting diagnosis and therapy
US7387772B1 (en) 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
JP3395673B2 (ja) * 1998-11-18 2003-04-14 株式会社豊田中央研究所 微小酸素電極を利用した特異的結合対測定方法
GB2345133A (en) * 1998-12-24 2000-06-28 Hypoguard Limited Polyspecific antibody immunodiagnostic device
JP2002537769A (ja) 1999-02-26 2002-11-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトエンドカインαおよび使用方法
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20040001826A1 (en) * 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
EP2275557A1 (en) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
CA2413160A1 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
MXPA02012434A (es) 2000-06-16 2004-09-06 Cambridge Antibody Tech Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
TWI327600B (en) 2000-11-28 2010-07-21 Medimmune Llc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
EP1683865A3 (en) 2001-02-02 2006-10-25 Eli Lilly & Company Mammalian proteins and in particular CD200
WO2002064612A2 (en) 2001-02-09 2002-08-22 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
WO2002098370A2 (en) * 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
MXPA03009408A (es) 2001-04-13 2004-01-29 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
US6867189B2 (en) * 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
EP2990417A1 (en) 2001-12-21 2016-03-02 Human Genome Sciences, Inc. Albumin insulin fusion protein
AU2003235791A1 (en) * 2002-01-08 2003-07-24 Chiron Corporation Gene products differentially expressed in cancerous breast cells and their methods of use
WO2003062395A2 (en) * 2002-01-18 2003-07-31 Bristol-Myers Squibb Company Predictor sets for tyrosine kinase pathways
CA2478239A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
EP2270049A3 (en) 2002-04-12 2011-03-09 Medimmune, Inc. Recombinant anti-interleukin-9-antibody
EP2070949B1 (en) 2002-06-10 2013-01-16 Vaccinex, Inc. C35 antibodies and their use in the treatment of cancer
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
DK1551876T3 (da) 2002-10-16 2011-06-14 Purdue Pharma Lp Antistoffer, der binder til celle-associerede ca 125/0722P og fremgangsmåder til anvendelse deraf
SE0203591D0 (sv) * 2002-12-04 2002-12-04 Siemens Elema Ab Förfarande för beredning av ett mediakament och en medicinsk anordning
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
EP1585815A4 (en) * 2003-01-21 2006-02-22 Bristol Myers Squibb Co A NEW ACYL-COENZYME A, MONOCLYLGLYCERIN ACYLTRANSFERASE-3 (MGAT3), CODING POLYNUCLEOTIDE, AND USES THEREOF
EP1594542B1 (en) 2003-02-20 2010-06-30 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
US20070065887A1 (en) * 2003-07-21 2007-03-22 Kinch Michael S Diagnosis of pre-cancerous conditions using pcdgf agents
WO2005055936A2 (en) * 2003-12-04 2005-06-23 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
WO2005058961A2 (en) * 2003-12-12 2005-06-30 Amgen Inc. Antibodies specific for human galanin, and uses thereof
ES2775204T3 (es) 2003-12-23 2020-07-24 Genentech Inc Nuevos anticuerpos anti IL13 y usos de los mismos
AU2005211725B2 (en) 2004-02-09 2010-07-15 Human Genome Sciences, Inc. Albumin fusion proteins
CN100376599C (zh) * 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
JP2008513540A (ja) 2004-09-21 2008-05-01 メディミューン，インコーポレーテッド 呼吸器合胞体ウイルスに対する抗体及び該ウイルス用のワクチンを製造する方法
EP1809326A4 (en) 2004-10-27 2009-11-04 Medimmune Inc MODULATION OF ANTIBODY SPECIFICITY BY MEASURING ADAPTATION OF ITS AFFINITY TO AN APPARENT ANTIGEN
WO2006073921A2 (en) * 2004-12-30 2006-07-13 The Rockefeller University Compositions and methods for enhanced dendritic cell maturation and function
KR101335798B1 (ko) 2005-02-15 2013-12-02 듀크 유니버시티 항-ｃｄ19 항체 및 종양학에서 이의 용도
JP4976376B2 (ja) * 2005-04-08 2012-07-18 メディミューン，エルエルシー 哺乳動物メタニューモウイルスに対する抗体
AU2006244445B2 (en) 2005-05-05 2013-04-18 Duke University Anti-CD19 antibody therapy for autoimmune disease
EP2301969B1 (en) 2005-05-06 2015-12-23 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
TWI391399B (zh) 2005-05-25 2013-04-01 Hoffmann La Roche 測定溶離多肽之鹽濃度之方法
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
US7482124B2 (en) * 2005-07-08 2009-01-27 Bristol-Myers Squibb Company Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
DK1904104T3 (da) 2005-07-08 2013-11-11 Biogen Idec Inc SP35-antistoffer og anvendelser heraf
EP1920057A4 (en) 2005-08-03 2009-03-18 Grains Res & Dev Corp POLYSACCHARIDE synthases
PT1919503E (pt) 2005-08-10 2015-01-05 Macrogenics Inc Identificação e manipulação de anticorpos com a regiões de fc variantes e métodos de utilização dos mesmos
US20070202512A1 (en) * 2005-08-19 2007-08-30 Bristol-Myers Squibb Company Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
SI2500030T2 (sl) 2005-11-04 2018-11-30 Genentech, Inc. Uporaba inhibitorjev komplementarnih procesov za zdravljenje očesnih bolezni
EP1945261A4 (en) 2005-11-07 2010-05-12 Scripps Research Inst COMPOSITIONS AND METHODS FOR CONTROLLING THE SPECIFICITY OF TISSUE FACTOR SIGNALING
US20070136826A1 (en) * 2005-12-02 2007-06-14 Biogen Idec Inc. Anti-mouse CD20 antibodies and uses thereof
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
EP2650306A1 (en) 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US7572625B2 (en) * 2006-05-18 2009-08-11 Boston Scientific Scimed, Inc. Medical devices coated with drug carrier macromolecules
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
BRPI0713426A2 (pt) 2006-06-14 2012-10-09 Macrogenics Inc métodos de tratar, diminuir a progressão, ou melhorar um ou mais sintomas de um distúrbio, e de prevenir ou retardar o inìcio de um distúrbio
CA2656918A1 (en) * 2006-06-22 2007-12-27 Vaccinex, Inc. Anti-c35 antibodies for treating cancer
SI2029173T1 (sl) 2006-06-26 2016-12-30 Macrogenics, Inc. Protitelesa, specifična za Fc RIIB, in postopki za njihovo uporabo
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
PT2594586E (pt) 2006-09-01 2014-11-26 Zymogenetics Inc Anticorpos monoclonais de il-31 e métodos de utilização
EP2061904A2 (en) 2006-09-06 2009-05-27 Ortho-McNeil Pharmaceutical, Inc. Biomarkers for assessing response to c-met treatment
WO2008048545A2 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
CA2699837C (en) 2006-12-01 2017-06-13 Seattle Genetics, Inc. Variant target binding agents and uses thereof
JP5386364B2 (ja) 2006-12-18 2014-01-15 ジェネンテック， インコーポレイテッド 抗Ｎｏｔｃｈ３アンタゴニスト抗体とＮｏｔｃｈ３関連疾患の予防及び治療におけるその使用
US8143071B2 (en) * 2006-12-21 2012-03-27 Phynexus, Inc. Method and device for extracting an analyte
PL2068887T3 (pl) 2007-01-09 2014-09-30 Biogen Ma Inc Przeciwciała przeciw sp35 i ich zastosowanie
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
US7807168B2 (en) * 2007-04-10 2010-10-05 Vaccinex, Inc. Selection of human TNFα specific antibodies
GB0707870D0 (en) 2007-04-23 2007-05-30 Selected Antibodies Ltd Assay Devices and Methods and Components for use Therein
EP2068925A4 (en) 2007-05-07 2011-08-31 Medimmune Llc ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES
ES2558689T3 (es) 2007-05-14 2016-02-08 Medimmune, Llc Métodos para reducir los niveles de eosinófilos
EP2014680A1 (en) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
EP2225275A4 (en) * 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
US10365224B2 (en) 2007-12-06 2019-07-30 Genalyte, Inc. Label-free optical sensors
KR101642846B1 (ko) 2007-12-26 2016-07-26 백시넥스 인코포레이티드 항-ｃ35 항체 병용 치료 및 방법
WO2009118300A1 (en) 2008-03-25 2009-10-01 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by down-regulating frizzled-4 and/or frizzled-1
PL2282773T3 (pl) 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
WO2009148896A2 (en) 2008-05-29 2009-12-10 Nuclea Biotechnologies, LLC Anti-phospho-akt antibodies
AU2009269099B2 (en) 2008-07-09 2016-03-10 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
US9003679B2 (en) * 2008-08-06 2015-04-14 Nike, Inc. Customization of inner sole board
US20120128684A1 (en) 2008-08-25 2012-05-24 Burnham Institute For Medical Research Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
AU2009294415B2 (en) 2008-09-19 2015-09-24 Medimmune Llc Antibodies directed to DLL4 and uses thereof
ES2939310T3 (es) 2008-10-27 2023-04-20 Genalyte Inc Biosensores basados en sondeo y detección ópticos
CN102272154A (zh) 2008-10-29 2011-12-07 惠氏有限责任公司 单域抗原结合性分子的纯化方法
CA2738243C (en) 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
EP2356251A1 (en) 2008-11-07 2011-08-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Teneurin and cancer
BRPI0921845A2 (pt) 2008-11-12 2019-09-17 Medimmune Llc formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
US20120114667A1 (en) 2008-12-23 2012-05-10 Medimmune Limited TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
AU2009334498A1 (en) 2008-12-31 2011-07-21 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US20110014190A1 (en) 2009-02-12 2011-01-20 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
WO2010100247A1 (en) 2009-03-06 2010-09-10 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Novel therapy for anxiety
EP2241323A1 (en) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W and brain cancers
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
JP6059013B2 (ja) 2009-05-08 2017-01-11 バクシネックス インコーポレーティッド 抗ｃｄ１００抗体およびこれを使用するための方法
JP5762408B2 (ja) 2009-08-13 2015-08-12 クルセル ホランド ベー ヴェー ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法
EP2292266A1 (en) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Treating cancer by modulating copine III
WO2011036118A1 (en) 2009-09-22 2011-03-31 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mex-3
WO2011041721A1 (en) 2009-10-02 2011-04-07 Biogen Idec Ma Inc. Methods of preventing and removing trisulfide bonds
JP5898082B2 (ja) 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
CN104961829B (zh) 2009-11-24 2018-08-21 米迪缪尼有限公司 针对b7-h1的靶向结合剂
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
WO2011107586A1 (en) 2010-03-05 2011-09-09 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, Smoc1, tenascin-c and brain cancers
WO2011131611A1 (en) 2010-04-19 2011-10-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulating xrn1
EP2580239A1 (en) 2010-06-10 2013-04-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mammalian sterile 20-like kinase 3
TWI539963B (zh) 2010-07-09 2016-07-01 庫賽爾荷蘭公司 抗－人類呼吸道融合性病毒（ｒｓｖ）抗體及其使用方法
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
CN108314733A (zh) 2010-07-16 2018-07-24 埃博灵克斯股份有限公司 修饰的单结构域抗原结合分子及其应用
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
SG188285A1 (en) 2010-09-02 2013-04-30 Vaccinex Inc Anti-cxcl13 antibodies and methods of using the same
WO2012032143A1 (en) 2010-09-10 2012-03-15 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Phosphorylated twist1 and metastasis
WO2012054748A2 (en) 2010-10-22 2012-04-26 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
RU2604490C2 (ru) 2010-11-05 2016-12-10 Займворкс Инк. ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
US9921165B2 (en) 2010-11-05 2018-03-20 Genalyte, Inc. Optical analyte detection systems and methods of use
EP2640738A1 (en) 2010-11-15 2013-09-25 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Anti-fungal agents
WO2012131053A1 (en) 2011-03-30 2012-10-04 Ablynx Nv Methods of treating immune disorders with single domain antibodies against tnf-alpha
CA2833477A1 (en) 2011-04-21 2012-10-26 Seattle Genetics, Inc. Novel binder-drug conjugates (adcs) and their use
WO2012158551A1 (en) 2011-05-13 2012-11-22 Biogen Idec Ma Inc. Methods of preventing and removing trisulfide bonds
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
WO2012168259A1 (en) 2011-06-06 2012-12-13 Novartis Forschungsstiftung, Zweigniederlassung Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
CN104053671A (zh) 2011-11-01 2014-09-17 生态学有限公司 治疗癌症的抗体和方法
EP2773664A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49 antibodies
AU2012332588B2 (en) 2011-11-01 2017-09-07 Bionomics, Inc. Methods of blocking cancer stem cell growth
AU2012332593B2 (en) 2011-11-01 2016-11-17 Bionomics, Inc. Anti-GPR49 antibodies
EP2773671B1 (en) 2011-11-04 2021-09-15 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
WO2013068431A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
EP2776838A1 (en) 2011-11-08 2014-09-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Early diagnostic of neurodegenerative diseases
MX2014007121A (es) 2011-12-14 2014-09-04 Seattle Genetics Inc Nuevos conjugados de principio activo-ligante (adc) y su uso.
EP2800583A1 (en) 2012-01-02 2014-11-12 Novartis AG Cdcp1 and breast cancer
EP2812702B1 (en) 2012-02-10 2019-04-17 Seattle Genetics, Inc. Diagnosis and management of CD30-expressing cancers
IN2014DN08199A (el) 2012-03-02 2015-05-01 Vaccinex Inc
US20130261010A1 (en) 2012-03-12 2013-10-03 The Board Of Trustees Of The University Of Illinois Optical analyte detection systems with magnetic enhancement and methods of use
EP2831112A1 (en) 2012-03-29 2015-02-04 Friedrich Miescher Institute for Biomedical Research Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
ES2843054T3 (es) 2012-05-10 2021-07-15 Zymeworks Inc Construcciones heteromultiméricas de cadenas pesadas de inmunoglobulina con mutaciones en el dominio Fc
WO2013172951A1 (en) 2012-05-15 2013-11-21 Morphotek, Inc. Methods for treatment of gastric cancer
MX369626B (es) 2012-05-24 2019-11-13 Mountgate Group Ltd Composiciones y metodos relacionados con la prevencion y el tratamiento de infecciones por rabia.
EP2862875B1 (en) 2012-06-14 2023-09-06 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION
EP2866831A1 (en) 2012-06-29 2015-05-06 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating diseases by modulating a specific isoform of mkl1
WO2014006114A1 (en) 2012-07-05 2014-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
US20150224190A1 (en) 2012-07-06 2015-08-13 Mohamed Bentires-Alj Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
ES2702315T3 (es) 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
EP2954048A1 (en) 2013-02-08 2015-12-16 Friedrich Miescher Institute for Biomedical Research Novel methods for the targeted introduction of viruses into cells
US20160002325A1 (en) 2013-03-08 2016-01-07 Vaccinex, Inc. Anti-cxcl13 antibodies and associated epitope sequences
WO2014143637A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The University Of Illinois Methods and compositions for enhancing immunoassays
CA2907181C (en) 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
AU2014262843B2 (en) 2013-05-06 2017-06-22 Scholar Rock, Inc. Compositions and methods for growth factor modulation
WO2015019286A1 (en) 2013-08-07 2015-02-12 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment friedreich's ataxia
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
CA3120508A1 (en) 2013-10-28 2015-05-07 Dots Technology Corp. Allergen detection
JPWO2015068847A1 (ja) * 2013-11-11 2017-03-09 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
CA2934617A1 (en) 2013-12-23 2015-07-02 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with kinesin spindle protein (ksp)
US9546214B2 (en) 2014-04-04 2017-01-17 Bionomics, Inc. Humanized antibodies that bind LGR5
RU2689145C2 (ru) 2014-04-16 2019-05-24 Биокон Лтд. Стабильные белковые препараты, содержащие молярный избыток сорбитола
ES2869459T3 (es) 2014-05-16 2021-10-25 Medimmune Llc Moléculas con unión a receptor de fc de neonato alterada que tiene propiedades terapéuticas y de diagnóstico potenciadas
EP3154579A1 (en) 2014-06-13 2017-04-19 Friedrich Miescher Institute for Biomedical Research New treatment against influenza virus
WO2015198202A1 (en) 2014-06-23 2015-12-30 Friedrich Miescher Institute For Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
AU2015280436A1 (en) 2014-06-23 2017-02-02 Bionomics, Inc. Antibodies that bind LGR4
EP3164129A1 (en) 2014-07-01 2017-05-10 Friedrich Miescher Institute for Biomedical Research Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
AU2015289831B2 (en) * 2014-07-14 2021-01-28 The Penn State Research Foundation Compositions and methods for targeting of the surfactant protein a receptor
WO2016029079A2 (en) 2014-08-21 2016-02-25 Walter Reed Army Institute Of Research Department Of The Army Monoclonal antibodies for treatment of microbial infections
US20170298360A1 (en) 2014-09-24 2017-10-19 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
EP4632120A2 (en) 2014-11-11 2025-10-15 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
SI3218005T1 (sl) 2014-11-12 2023-06-30 Seagen Inc. Z glikanom delujoče spojine, in postopki uporabe
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US11033637B2 (en) 2014-11-21 2021-06-15 University Of Maryland, Baltimore Targeted structure-specific particulate delivery systems
US10485880B2 (en) 2014-12-15 2019-11-26 Bayer Pharma Aktiengesellschaft Antibody-drug conjugates (ADCs) of KSP inhibitors with aglycosylated anti-TWEAKR antibodies
HUE053097T2 (hu) 2015-03-31 2021-06-28 Medimmune Ltd Új IL33 forma, IL33 mutáltatott formái, ellenanyagok, vizsgálati eljárások és eljárások azok alkalmazására
JP6971858B2 (ja) 2015-06-22 2021-11-24 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ）
CN108025086A (zh) 2015-06-23 2018-05-11 拜耳制药股份公司 Ksp抑制剂与抗b7h3抗体的抗体-活性物质缀合物(adc)
EP3313521A1 (de) 2015-06-23 2018-05-02 Bayer Pharma Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-tweakr-antikörpern
AU2016282724A1 (en) 2015-06-23 2018-01-18 Bayer Pharma Aktiengesellschaft Targeted conjugates of KSP inhibitors
WO2017031353A1 (en) 2015-08-19 2017-02-23 Rutgers, The State University Of New Jersey Novel methods of generating antibodies
EP3349791A1 (en) 2015-09-15 2018-07-25 Board of Regents, The University of Texas System T-cell receptor (tcr)-binding antibodies and uses thereof
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
EP3368566A1 (en) 2015-10-28 2018-09-05 Friedrich Miescher Institute for Biomedical Research Tenascin-w and biliary tract cancers
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP3432925A4 (en) 2016-03-22 2019-11-06 Bionomics Limited ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY
JP7251981B2 (ja) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
CN109310781B (zh) 2016-06-15 2024-06-18 拜耳制药股份公司 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc)
US11447542B2 (en) 2016-08-05 2022-09-20 Medimmune, Llc Anti-O2 antibodies and uses thereof
EP3512548B1 (en) 2016-09-16 2023-03-22 Bionomics Limited Antibody and checkpoint inhibitor combination therapy
KR20190064636A (ko) 2016-10-19 2019-06-10 메디뮨 엘엘씨 항-o1 항체 및 이의 용도
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
JP7106538B2 (ja) 2016-12-07 2022-07-26 アジェナス インコーポレイテッド 抗体およびその使用方法
US11660351B2 (en) 2016-12-21 2023-05-30 Bayer Aktiengesellschaft Antibody drug conjugates (ADCs) having enzymatically cleavable groups
WO2018114804A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
US12059472B2 (en) 2016-12-21 2024-08-13 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
EP3589319A4 (en) 2017-03-03 2021-07-14 Seagen Inc. COMPOUNDS INTERACTING WITH GLYCAN AND METHODS OF USE
BR112019022108A2 (pt) 2017-04-22 2020-05-12 Immunomic Therapeutics, Inc. Construções de lamp aprimoradas
KR20200016224A (ko) 2017-05-02 2020-02-14 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
JP7366755B2 (ja) 2017-05-30 2023-10-23 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ 抗ダブルコルチン様キナーゼ１抗体および使用方法
WO2018237148A1 (en) 2017-06-21 2018-12-27 Gilead Sciences, Inc. Multispecific antibodies that target hiv gp120 and cd3
EP3668969A1 (en) 2017-08-18 2020-06-24 Friedrich Miescher Institute for Biomedical Research Novel methods for the targeted introduction of viruses into cells and tissues
IL316538A (en) 2017-10-11 2024-12-01 Seagen Inc Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
WO2019073069A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
US20220226439A1 (en) 2017-11-01 2022-07-21 Seagen Inc. Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
US11591385B2 (en) 2017-11-09 2023-02-28 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
EP3720963A4 (en) 2017-12-05 2021-12-08 Chugai Seiyaku Kabushiki Kaisha ANTIGEN BINDING MOLECULE INCLUDING A VARIABLE REGION OF MODIFIED ANTIBODIES BINDING TO CD3 AND CD137
CA3089754A1 (en) 2018-01-31 2019-08-08 Bayer Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
AU2019240403A1 (en) 2018-03-23 2020-10-08 Seagen Inc. Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
BR112020022265A2 (pt) 2018-05-07 2021-02-23 Genmab A/S método para tratar câncer em um indivíduo, e, estojo.
CN112739716B (zh) 2018-05-07 2025-05-27 展马博联合股份有限公司 使用抗pd-1抗体与抗组织因子抗体-药物偶联物的组合治疗癌症的方法
CA3100004A1 (en) 2018-05-15 2019-11-21 Immunomic Therapeutics, Inc. Improved lamp constructs comprising allergens
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
MX2020013832A (es) 2018-06-18 2021-03-25 Bayer Ag Conjugados de ligante/agente activo dirigidos contra cxcr5 que tienen enlazadores escindibles enzimaticamente y un perfil de actividad mejorado.
SG11202012043RA (en) 2018-07-03 2021-01-28 Gilead Sciences Inc Antibodies that target hiv gp120 and methods of use
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CA3106829A1 (en) 2018-08-03 2020-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing two antigen-binding domains that are linked to each other
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
US20200102399A1 (en) 2018-10-01 2020-04-02 Seattle Genetics, Inc. Methods of Treating Peripheral T Cell Lymphoma Using Anti-CD30 Antibody Drug Conjugate Therapy
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
WO2020163225A1 (en) 2019-02-05 2020-08-13 Seattle Genetics, Inc. Anti-cd228 antibodies and antibody-drug conjugates
KR20210152472A (ko) 2019-03-11 2021-12-15 메모리얼 슬로안 케터링 캔서 센터 Cd22 항체 및 이를 사용하는 방법
JP7662531B2 (ja) 2019-03-28 2025-04-15 ダニスコ・ユーエス・インク 改変抗体
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
EP4013506A1 (en) 2019-08-12 2022-06-22 Aptevo Research and Development LLC 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
MX2022003357A (es) 2019-09-25 2022-05-03 Seagen Inc Combinación de anticuerpo anti-cd30 conjugado con un farmaco, anti-pd-1 y quimioterapia para el tratamiento de cánceres hematopoyéticos.
EP4038101A2 (en) 2019-10-04 2022-08-10 Seagen Inc. Anti-pd-l1 antibodies and antibody-drug conjugates
AU2020366515A1 (en) 2019-10-18 2022-04-21 Immunomic Therapeutics, Inc. Improved lamp constructs comprising cancer antigens
MX2022005240A (es) 2019-11-04 2022-08-19 Seagen Inc Conjugados de farmaco-anticuerpo anti-cd30 y su uso para el tratamiento de infeccion por vih.
TW202131954A (zh) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
CA3155754A1 (en) 2019-11-07 2021-05-14 Reshma Abdulla RANGWALA Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
TWI877278B (zh) 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
AU2021212193A1 (en) 2020-01-31 2022-09-08 Celgene Corporation Anti-CD30 antibody-drug conjugates and their use for the treatment of non-Hodgkin lymphoma
CN115397866B (zh) 2020-03-31 2025-10-31 中外制药株式会社 靶向dll3的多特异性抗原结合分子及其用途
AU2021273256A1 (en) 2020-05-13 2022-12-15 Seagen Inc. Methods of treating cancer using a combination of anti-CD30 antibody-drug conjugates
EP4192871A1 (en) 2020-08-04 2023-06-14 Seagen Inc. Anti-cd228 antibodies and antibody-drug conjugates
IL300917A (en) 2020-09-04 2023-04-01 Univ Rutgers Vaccines and antibodies to SARS-COV-2
US20230382978A1 (en) 2020-10-15 2023-11-30 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
AU2021383611A1 (en) 2020-11-17 2023-06-29 Peter Maccallum Cancer Institute Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
US20240301086A1 (en) 2020-12-01 2024-09-12 Aptevo Research And Development Llc Tumor-associated antigens and cd3-binding proteins, related compositions, and methods
CN117157318A (zh) 2020-12-30 2023-12-01 免疫治疗有限公司 抗hvem抗体
MX2023008261A (es) 2021-01-13 2023-09-12 Memorial Sloan Kettering Cancer Center Conjugado de anticuerpo-derivado de pirrolobenzodiazepina.
AU2022208361A1 (en) 2021-01-13 2023-07-27 Daiichi Sankyo Company, Limited Anti-dll3 antibody-drug conjugate
US20250199013A1 (en) 2021-05-28 2025-06-19 Alexion Pharmaceuticals, Inc. Methods for detecting cm-tma biomarkers
EP4355776A1 (en) 2021-06-14 2024-04-24 Argenx BV Anti-il-9 antibodies and methods of use thereof
TW202317190A (zh) 2021-06-29 2023-05-01 美商思進公司 以非岩藻糖基化抗ｃｄ７０抗體及ｃｄ４７拮抗劑之組合治療癌症之方法
AU2022312698A1 (en) 2021-07-13 2024-01-25 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
JP2024536383A (ja) 2021-10-06 2024-10-04 ジェンマブ エー／エス 併用におけるｐｄ－ｌ１およびｃｄ１３７に対する多重特異性結合剤
MX2024005080A (es) 2021-10-29 2024-05-13 Seagen Inc Metodos para tratar cancer con una combinacion de un anticuerpo anti-pd-1 y un conjugado de anticuerpo anti-cd30-farmaco.
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
WO2023192436A1 (en) 2022-03-31 2023-10-05 Alexion Pharmaceuticals, Inc. Singleplex or multiplexed assay for complement markers in fresh biological samples
EP4508071A1 (en) 2022-04-10 2025-02-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
US20250302982A1 (en) 2022-05-06 2025-10-02 Genmab A/S Methods of treating cancer with anti-tissue factor antibody-drug conjugates
CA3266977A1 (en) 2022-09-06 2024-03-14 Alexion Pharmaceuticals, Inc. DIAGNOSTIC AND PROGNOSIS BIOMARKER PROFILES IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA)
AU2023372538A1 (en) 2022-11-03 2025-05-01 Seagen Inc. Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer
CN120417937A (zh) 2022-11-17 2025-08-01 赛诺菲 Ceacam5抗体-药物缀合物及其使用方法
WO2024105205A1 (en) 2022-11-17 2024-05-23 Bayer Aktiengesellschaft Antibody-drug conjugates (a2dcs) with enzymatically cleavable groups
AU2023401158A1 (en) 2022-12-01 2025-05-29 BioNTech SE Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
KR20250173600A (ko) 2023-03-17 2025-12-10 옥시토프 파마 비.브이. 항-포스포콜린 항체 및 그 사용 방법
WO2024209072A1 (en) 2023-04-06 2024-10-10 Genmab A/S Multispecific binding agents against pd-l1 and cd137 for treating cancer
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2025072888A2 (en) 2023-09-28 2025-04-03 Novavax, Inc. Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025155971A1 (en) 2024-01-19 2025-07-24 Immunomic Therapeutics, Inc Anti-activin receptor 1c (alk-7) receptor antibodies
WO2025163468A1 (en) 2024-01-30 2025-08-07 Seagen Inc. Anti-pd-l1 antibodies and antibody-drug conjugates and their use in the treatment of cancer
WO2025196639A1 (en) 2024-03-21 2025-09-25 Seagen Inc. Cd25 antibodies, antibody-drug conjugates, and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401764A (en) * 1980-02-07 1983-08-30 Technicon Instruments Corporation Immunoassays employing labeled reagent and a conjugate having two binding sites
JP3177776B2 (ja) * 1988-09-27 2001-06-18 武田薬品工業株式会社 ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤
CA1213229A (en) * 1982-04-12 1986-10-28 Gary S. David Antibodies having dual specificities, their preparation and uses therefor
US4446233A (en) * 1982-05-05 1984-05-01 E. I. Du Pont De Nemours And Company Homogeneous immunoassay using covalent hybrid antibodies
CA1194415A (en) * 1982-05-05 1985-10-01 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
IT1199088B (it) * 1984-03-09 1988-12-30 Miles Italiana Saggio di legame specifico mediante impiego di anti-g6pdh come marcante
EP0329184A3 (en) * 1988-02-19 1990-05-23 Neorx Corporation Antimers and antimeric conjugation
AU4402589A (en) * 1988-09-28 1990-04-18 Ideon Corporation Combination enzyme immunotherapeutics
IT1235349B (it) * 1988-12-23 1992-06-30 Biodata Spa Saggio immunologico per determinazioni in fase omogenea
AU6290090A (en) * 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
CA2069439A1 (en) * 1989-12-15 1991-06-16 Susumu Iwasa Monoclonal antibodies, their production and use
EP0515571B1 (en) * 1990-02-16 1998-12-02 Boston Biomedical Research Institute Hybrid reagents capable of selectively releasing molecules into cells
US5273743A (en) * 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent

Also Published As

Publication number Publication date
AP257A (en) 1993-06-03
EP0582595A1 (en) 1994-02-16
EP0511011A1 (en) 1992-10-28
DK0511011T3 (da) 1997-03-10
ATE144624T1 (de) 1996-11-15
AP9200376A0 (en) 1992-04-30
AU665758B2 (en) 1996-01-18
HU9303026D0 (en) 1994-01-28
IL101690A (en) 1996-12-05
CN1069124A (zh) 1993-02-17
JP3431140B2 (ja) 2003-07-28
EP0511011B1 (en) 1996-10-23
JPH06506827A (ja) 1994-08-04
US5573920A (en) 1996-11-12
CA2108451A1 (en) 1992-10-27
IE921342A1 (en) 1992-11-04
IL101690A0 (en) 1992-12-30
DE69214709T2 (de) 1997-02-20
US5855886A (en) 1999-01-05
NZ242510A (en) 1994-08-26
CN1047666C (zh) 1999-12-22
AU1661892A (en) 1992-12-21
HUT66753A (en) 1994-12-28
WO1992019973A1 (en) 1992-11-12
DE69214709D1 (de) 1996-11-28
ES2093778T3 (es) 1997-01-01

Similar Documents

Publication Publication Date Title
AP9200376A0 (en) Novel antibodies and methods for their use
GB8905669D0 (en) Modified antibodies
EP0466505A3 (en) Artificial antibody
EP0499233A3 (en) Organopentasiloxane and method for its preparation
EP0240344A3 (en) Monoclonal antibodies and their use
GB9412166D0 (en) Retargetting antibodies
EP0508427A3 (en) Method and kit for measuring anti-ebna antibodies
EP0285511A3 (en) Monoclonal antibodies and their uses
EP0506523A3 (en) Monoclonal antibodies
IL116967A (en) Ethyl-6-formyloxy-4-hexenoate and process for the preparation thereof
GB9102616D0 (en) Antibodies and their use as drug vectors
GB9122721D0 (en) Methods
GB9120768D0 (en) Diagnostic and prognastic materials and methods
GB9223676D0 (en) Modified antibodies
EP0491351A3 (en) Chimeric antibodies and their use
GB9014652D0 (en) Antigen
GB9118966D0 (en) Celaning apparatus and methods
GB8830115D0 (en) Monoclonal antibody and preparation and use thereof
GB9115010D0 (en) Antibody
EP0458475A3 (en) Transpeptidation reagent and method
ZA922978B (en) Novel antibodies and methods for their use.
GB8812137D0 (en) Antibodies
EP0423333A4 (en) Anti-endoserine antibody
GB9118013D0 (en) Monoclonal antibodies and their use
GB9004634D0 (en) An antibody and use thereof